FindTrial
Sign In

MS-553

DRUG5 trials

Sponsors

MingSight Pharmaceuticals Pty Limited, MingSight Pharmaceuticals, Inc, Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Conditions

Aggressive LymphomaChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Diabetic Macular EdemaDiabetic RetinopathyDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Lymphocytic Leukemia

Phase 1

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers
CompletedNCT02406989
MingSight Pharmaceuticals Pty LimitedSafety and PK in Healthy Volunteers
Start: 2015-04-30End: 2015-09-30Updated: 2016-03-16
A Study Of The Selective PKC-β Inhibitor MS- 553
TerminatedNCT03492125
MingSight Pharmaceuticals, IncAggressive Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Start: 2018-05-25End: 2023-11-28Updated: 2025-04-10
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
RecruitingNCT04187443
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema +2
Start: 2020-06-02End: 2026-12-30Target: 45Updated: 2025-09-29
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
TerminatedNCT05272813
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Start: 2022-04-28End: 2023-11-28Updated: 2024-07-18
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
TerminatedNCT05720052
MingSight Pharmaceuticals, IncChronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) +4
Start: 2023-02-06End: 2023-11-28Updated: 2024-07-18

Related Papers

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia
Blood2023-11-02
MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL
Blood2023-11-02
Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL
Blood2022-11-157 citations